Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience

Scott G Houghton1, David R Farley, Michael D Brennan

  • 1Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

World Journal of Surgery
|October 19, 2004
PubMed

Insights

Thyroidectomy offers an effective treatment for amiodarone-associated thyrotoxicosis (AAT), particularly when medical management fails. However, this surgical approach carries significant risks, including perioperative complications and mortality, especially in patients with underlying cardiac conditions.

Area of Science:

  • Endocrinology
  • Cardiology
  • Surgical Oncology

Background:

  • Amiodarone-associated thyrotoxicosis (AAT) presents challenges due to underlying cardiac disease and resistance to medical therapy.
  • Surgical intervention is considered for AAT patients refractory to or intolerant of medical management, or those requiring continued amiodarone therapy.

Observation:

  • A retrospective review of 34 patients (29 men, 5 women; median age 60) undergoing thyroidectomy for AAT between 1985 and 2002.
  • Common symptoms included worsening heart failure, fatigue, weight loss, and tremor. Indications for surgery included medically refractory disease, cardiac decompensation, and severe symptoms.
  • The median American Society of Anesthesiologists (ASA) classification was 3, indicating significant comorbidity.

Findings:

  • Thyroidectomy was performed on patients with AAT, with 12 failing prior medical management and 21 receiving no preoperative therapy.
  • Histology confirmed AAT in 27 specimens. Complications included mortality (n=3), rehospitalization (n=3), symptomatic hypocalcemia (n=2), and other serious events.
  • Of 31 survivors, 80% continued amiodarone post-surgery. At a median follow-up of 29 months, all survivors were free of hyperthyroid symptoms.

Implications:

  • Thyroidectomy is an effective treatment for amiodarone-associated thyrotoxicosis, achieving symptom resolution.
  • The high rate of perioperative morbidity and mortality highlights the risks associated with this procedure in a high-risk patient population.
  • Careful patient selection and risk assessment are crucial for managing AAT surgically, considering the significant cardiovascular comorbidities.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...